BRIEF published on 06/18/2025 at 07:05, 5 months 29 days ago PHAXIAM Therapeutics suspends trading of its shares Euronext Paris Innovative Treatments PHAXIAM Suspension Of Quotation Delisting Securities
PRESS RELEASE published on 06/18/2025 at 07:00, 5 months 29 days ago Inside Information / Other news releases PHAXIAM Therapeutics suspends trading shares for delisting on Euronext Paris market. No reimbursement to shareholders. Company focuses on innovative phage-based treatments for resistant bacterial infections Trading Delisting Suspension PHAXIAM Therapeutics Phage-based Treatments
BRIEF published on 06/05/2025 at 07:05, 6 months 12 days ago PHAXIAM Therapeutics Facing Potential Liquidation Amid Court Hearing Postponement Biopharmaceuticals Judicial Liquidation Court Hearing PHAXIAM Therapeutics Euronext Delisting
PRESS RELEASE published on 06/05/2025 at 07:00, 6 months 12 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces new postponement of Offer Review Hearing by Lyon Commercial Court to June 11, 2025. Company to request delisting from Euronext Euronext Delisting Postponement PHAXIAM Therapeutics Lyon Commercial Court
BRIEF published on 03/14/2025 at 17:50, 9 months 3 days ago PHAXIAM Therapeutics seeks buyer in receivership Euronext Paris PHAXIAM Therapeutics Judicial Recovery Looking For A Buyer Extension Of Procedure
PRESS RELEASE published on 03/14/2025 at 17:45, 9 months 3 days ago Inside Information / Other news releases PHAXIAM Therapeutics launches bidding process to find buyers amid receivership, trading of shares to resume on Euronext Paris. Court decides on procedure extension on April 30, 2025 Euronext Paris Receivership PHAXIAM Therapeutics Court Decision Bidding Process
BRIEF published on 03/06/2025 at 18:01, 9 months 11 days ago PHAXIAM Therapeutics Enters Receivership and Delays Financial Results Trading Suspension Financial Results Delay PHAXIAM Receivership Biotech Challenges Court-appointed Administrator
PRESS RELEASE published on 03/06/2025 at 17:56, 9 months 11 days ago Inside Information / Other news releases PHAXIAM Therapeutics announces the opening of a receivership procedure and postponement of its 2024 financial results publication. The company continues operations under observation period Financial Results Biopharmaceutical Company PHAXIAM Therapeutics Receivership Procedure Phage-based Treatments
BRIEF published on 03/06/2025 at 11:45, 9 months 11 days ago Suspension of the Listing of PHAXIAM Therapeutics Euronext Paris Biopharmaceutical PHAXIAM Therapeutics Suspension Of Quotation Resistant Infections
BRIEF published on 12/30/2024 at 17:50, 11 months 18 days ago PHAXIAM Therapeutics: Promising results from the PhagoDAIR pilot study Infection Control PHAXIAM Therapeutics Phase II GLORIA PhagoDAIR Study Anti-S. Aureus Phages
Published on 12/17/2025 at 15:00, 4 hours 35 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 5 hours 35 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 6 hours ago Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 6 hours 20 minutes ago Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers
Published on 12/17/2025 at 13:00, 6 hours 35 minutes ago Gold Terra Provides a Summary of 2025 Achievements and 2026 Plan
Published on 12/17/2025 at 19:10, 25 minutes ago Holand Automotive Group Announces the sale of Ferrari Rancho Mirage to Lapis Automotive Group
Published on 12/17/2025 at 18:39, 56 minutes ago EQS-Adhoc: centrotherm international AG: Centrotherm AcquiCo AG submits request for the squeeze-out of minority shareholders of centrotherm international AG
Published on 12/17/2025 at 18:05, 1 hour 30 minutes ago Valour Inc. Launches Constant Leveraged Bitcoin and Ethereum ETPs on Spotlight Stock Market
Published on 12/17/2025 at 17:32, 2 hours 2 minutes ago EQS-Adhoc: Raiffeisen Bank International AG: Michael Höllerer will succeed Johann Strobl as CEO of RBI on 1 July 2026
Published on 12/17/2025 at 18:00, 1 hour 35 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
Published on 12/17/2025 at 17:51, 1 hour 44 minutes ago Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure
Published on 12/17/2025 at 17:50, 1 hour 45 minutes ago The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.
Published on 12/17/2025 at 17:45, 1 hour 50 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2025
